Biomason, a Reserch Triangle Park, NC-based company employing biology to produce cement, raised $65M in Series C funding.
The financing was led by 2150, with participation from Celesta Capital, Novo Holdings and Martin Marietta Materials.
The company intends to use the funds to accelerate development of the biocement® technology platform to reach its goal of eliminating 25% of global carbon emissions from the concrete industry by 2030.
Founded in 2021 by CEO Ginger Krieg Dosier, Biomason employs natural microorganisms to grow biocement in ambient temperatures without emitting carbon dioxide. Its patented biocement technology mimics nature’s use of carbon as a building block, creating cement in a biological, circular system, rather than relying on climate-intensive Portland cement (OPC) production process. The company has installed biocement-powered products throughout North America and Europe, demonstrated novel biocement applications in collaboration with DARPA, and entered into agreements with global companies, including H&M Group and IBF to further scale biocement applications.
FinSMEs
28/02/2022